<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD07680000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P04275</UniProt_ID>
  <Seq_Length>2813</Seq_Length>
  <Molecule_Weight>309265</Molecule_Weight>
  <KEGG_ID>hsa:7450</KEGG_ID>
  <Orthology_ID>K03900</Orthology_ID>
  <EBI_ID>EBI-981819</EBI_ID>
  <Function_Summary>Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.</Function_Summary>
  <Pfam_ID>PF08742:C8@@PF01826:TIL@@PF00092:VWA@@PF00093:VWC@@PF00094:VWD</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>von Willebrand antigen 2</Alias>
      <Alias>von Willebrand antigen II</Alias>
      <Alias>vWF</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protease or peptidase.</Detail>
      <Keyword>Protease binding</Keyword>
      <Ontology_ID>GO:0002020</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a glycoprotein, a protein that contains covalently bound glycose (monosaccharide) residues. These also include proteoglycans.</Detail>
      <Keyword>Glycoprotein binding</Keyword>
      <Ontology_ID>GO:0001948</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with collagen, a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. Collagen is highly enriched in glycine (some regions are 33% glycine) and proline, occurring predominantly as 3-hydroxyproline (about 20%).</Detail>
      <Keyword>Collagen binding</Keyword>
      <Ontology_ID>GO:0005518</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a chaperone protein, a class of proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport.</Detail>
      <Keyword>Chaperone binding</Keyword>
      <Ontology_ID>GO:0051087</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein N-terminus, the end of any peptide chain at which the 2-amino (or 2-imino) function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue.</Detail>
      <Keyword>Protein N-terminus binding</Keyword>
      <Ontology_ID>GO:0047485</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an integrin.</Detail>
      <Keyword>Integrin binding</Keyword>
      <Ontology_ID>GO:0005178</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein to form a homodimer.</Detail>
      <Keyword>Protein homodimerization activity</Keyword>
      <Ontology_ID>GO:0042803</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an immunoglobulin.</Detail>
      <Keyword>Immunoglobulin binding</Keyword>
      <Ontology_ID>GO:0019865</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>1628</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>1314</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>1584</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>2739</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>1306</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>1648</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1266</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>791</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>852</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>857</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>1324</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1565</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>2185</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>273</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>1597</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>1461</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1318</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>1472</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>1149</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1374</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>1638</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>1613</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>885</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1381</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>2063</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1272</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>2178</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1540</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>1597</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>788</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>1308</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>1570</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>1514</Position>
      <Original>Phe</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>484</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>2546</Position>
      <Original>Asn</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>1313</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>471</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>1060</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>550</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>2705</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1272</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>789</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>2773</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>816</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>1460</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>1399</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>1597</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>740</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>2362</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>1316</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>1665</Position>
      <Original>Val</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>377</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>1374</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>1607</Position>
      <Original>Val</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>1268</Position>
      <Original>His</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>528</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>1609</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>1341</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>854</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers.</Detail>
      <Keyword>Blood coagulation</Keyword>
      <Ontology_ID>GO:0007596</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A protein activation cascade that contributes to blood coagulation and consists of the interactions among high molecular weight kininogen, prekallikrein, and factor XII that lead to the activation of clotting factor X.</Detail>
      <Keyword>Blood coagulation, intrinsic pathway</Keyword>
      <Ontology_ID>GO:0007597</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The regulated exocytosis of secretory granules containing preformed mediators such as histamine and serotonin by a platelet.</Detail>
      <Keyword>Platelet degranulation</Keyword>
      <Ontology_ID>GO:0002576</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell to the underlying substrate via adhesion molecules.</Detail>
      <Keyword>Cell-substrate adhesion</Keyword>
      <Ontology_ID>GO:0031589</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.</Detail>
      <Keyword>Cell adhesion</Keyword>
      <Ontology_ID>GO:0007155</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stopping of bleeding (loss of body fluid) or the arrest of the circulation to an organ or part.</Detail>
      <Keyword>Hemostasis</Keyword>
      <Ontology_ID>GO:0007599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug.</Detail>
      <Keyword>Platelet activation</Keyword>
      <Ontology_ID>GO:0030168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of identical component monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.</Detail>
      <Keyword>Protein homooligomerization</Keyword>
      <Ontology_ID>GO:0051260</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MIPARFAGVLLALALILPGTLCAEGTRGRSSTARCSLFGSDFVNTFDGSMYSFAGYCSYLLAGGCQKRSFSIIGDFQNGKRVSLSVYLGEFFDIHLFVNGTVTQGDQRVSMPYASKGLYLETEAGYYKLSGEAYGFVARIDGSGNFQVLLSDRYFNKTCGLCGNFNIFAEDDFMTQEGTLTSDPYDFANSWALSSGEQWCERASPPSSSCNISSGEMQKGLWEQCQLLKSTSVFARCHPLVDPEPFVALCEKTLCECAGGLECACPALLEYARTCAQEGMVLYGWTDHSACSPVCPAGMEYRQCVSPCARTCQSLHINEMCQERCVDGCSCPEGQLLDEGLCVESTECPCVHSGKRYPPGTSLSRDCNTCICRNSQWICSNEECPGECLVTGQSHFKSFDNRYFTFSGICQYLLARDCQDHSFSIVIETVQCADDRDAVCTRSVTVRLPGLHNSLVKLKHGAGVAMDGQDVQLPLLKGDLRIQHTVTASVRLSYGEDLQMDWDGRGRLLVKLSPVYAGKTCGLCGNYNGNQGDDFLTPSGLAEPRVEDFGNAWKLHGDCQDLQKQHSDPCALNPRMTRFSEEACAVLTSPTFEACHRAVSPLPYLRNCRYDVCSCSDGRECLCGALASYAAACAGRGVRVAWREPGRCELNCPKGQVYLQCGTPCNLTCRSLSYPDEECNEACLEGCFCPPGLYMDERGDCVPKAQCPCYYDGEIFQPEDIFSDHHTMCYCEDGFMHCTMSGVPGSLLPDAVLSSPLSHRSKRSLSCRPPMVKLVCPADNLRAEGLECTKTCQNYDLECMSMGCVSGCLCPPGMVRHENRCVALERCPCFHQGKEYAPGETVKIGCNTCVCQDRKWNCTDHVCDATCSTIGMAHYLTFDGLKYLFPGECQYVLVQDYCGSNPGTFRILVGNKGCSHPSVKCKKRVTILVEGGEIELFDGEVNVKRPMKDETHFEVVESGRYIILLLGKALSVVWDRHLSISVVLKQTYQEKVCGLCGNFDGIQNNDLTSSNLQVEEDPVDFGNSWKVSSQCADTRKVPLDSSPATCHNNIMKQTMVDSSCRILTSDVFQDCNKLVDPEPYLDVCIYDTCSCESIGDCACFCDTIAAYAHVCAQHGKVVTWRTATLCPQSCEERNLRENGYECEWRYNSCAPACQVTCQHPEPLACPVQCVEGCHAHCPPGKILDELLQTCVDPEDCPVCEVAGRRFASGKKVTLNPSDPEHCQICHCDVVNLTCEACQEPGGLVVPPTDAPVSPTTLYVEDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDGSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRITLLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPDMAQVTVGPGLLGVSTLGPKRNSMVLDVAFVLEGSDKIGEADFNRSKEFMEEVIQRMDVGQDSIHVTVLQYSYMVTVEYPFSEAQSKGDILQRVREIRYQGGNRTNTGLALRYLSDHSFLVSQGDREQAPNLVYMVTGNPASDEIKRLPGDIQVVPIGVGPNANVQELERIGWPNAPILIQDFETLPREAPDLVLQRCCSGEGLQIPTLSPAPDCSQPLDVILLLDGSSSFPASYFDEMKSFAKAFISKANIGPRLTQVSVLQYGSITTIDVPWNVVPEKAHLLSLVDVMQREGGPSQIGDALGFAVRYLTSEMHGARPGASKAVVILVTDVSVDSVDAAADAARSNRVTVFPIGIGDRYDAAQLRILAGPAGDSNVVKLQRIEDLPTMVTLGNSFLHKLCSGFVRICMDEDGNEKRPGDVWTLPDQCHTVTCQPDGQTLLKSHRVNCDRGLRPSCPNSQSPVKVEETCGCRWTCPCVCTGSSTRHIVTFDGQNFKLTGSCSYVLFQNKEQDLEVILHNGACSPGARQGCMKSIEVKHSALSVELHSDMEVTVNGRLVSVPYVGGNMEVNVYGAIMHEVRFNHLGHIFTFTPQNNEFQLQLSPKTFASKTYGLCGICDENGANDFMLRDGTVTTDWKTLVQEWTVQRPGQTCQPILEEQCLVPDSSHCQVLLLPLFAECHKVLAPATFYAICQQDSCHQEQVCEVIASYAHLCRTNGVCVDWRTPDFCAMSCPPSLVYNHCEHGCPRHCDGNVSSCGDHPSEGCFCPPDKVMLEGSCVPEEACTQCIGEDGVQHQFLEAWVPDHQPCQICTCLSGRKVNCTTQPCPTAKAPTCGLCEVARLRQNADQCCPEYECVCDPVSCDLPPVPHCERGLQPTLTNPGECRPNFTCACRKEECKRVSPPSCPPHRLPTLRKTQCCDEYECACNCVNSTVSCPLGYLASTATNDCGCTTTTCLPDKVCVHRSTIYPVGQFWEEGCDVCTCTDMEDAVMGLRVAQCSQKPCEDSCRSGFTYVLHEGECCGRCLPSACEVVTGSPRGDSQSSWKSVGSQWASPENPCLINECVRVKEEVFIQQRNVSCPQLEVPVCPSGFQLSCKTSACCPSCRCERMEACMLNGTVIGPGKTVMIDVCTTCRCMVQVGVISGFKLECRKTTCNPCPLGYKEENNTGECCGRCLPTACTIQLRGGQIMTLKRDETLQDGCDTHFCKVNERGEYFWEKRVTGCPPFDEHKCLAEGGKIMKIPGTCCDTCEEPECNDITARLQYVKVGSCKSEVEVDIHYCQGKCASKAMYSIDINDVQDQCSCCSPTRTEPMQVALHCTNGSVVYHEVLNAMECKCSPRKCSK</Protein_Seq>
    <DNA_Seq>AGCTCACAGCTATTGTGGTGGGAAAGGGAGGGTGGTTGGTGGATGTCACAGCTTGGGCTTTATCTCCCCCAGCAGTGGGGACTCCACAGCCCCTGGGCTACATAACAGCAAGACAGTCCGGAGCTGTAGCAGACCTGATTGAGCCTTTGCAGCAGCTGAGAGCATGGCCTAGGGTGGGCGGCACCATTGTCCAGCAGCTGAGTTTCCCAGGGACCTTGGAGATAGCCGCAGCCCTCATTTGCAGGGGAAGATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACCCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGTGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTCCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAGAGAGTGAGCCTCTCCGTGTATCTTGGGGAATTTTTTGACATCCATTTGTTTGTCAATGGTACCGTGACACAGGGGGACCAAAGAGTCTCCATGCCCTATGCCTCCAAAGGGCTGTATCTAGAAACTGAGGCTGGGTACTACAAGCTGTCCGGTGAGGCCTATGGCTTTGTGGCCAGGATCGATGGCAGCGGCAACTTTCAAGTCCTGCTGTCAGACAGATACTTCAACAAGACCTGCGGGCTGTGTGGCAACTTTAACATCTTTGCTGAAGATGACTTTATGACCCAAGAAGGGACCTTGACCTCGGACCCTTATGACTTTGCCAACTCATGGGCTCTGAGCAGTGGAGAACAGTGGTGTGAACGGGCATCTCCTCCCAGCAGCTCATGCAACATCTCCTCTGGGGAAATGCAGAAGGGCCTGTGGGAGCAGTGCCAGCTTCTGAAGAGCACCTCGGTGTTTGCCCGCTGCCACCCTCTGGTGGACCCCGAGCCTTTTGTGGCCCTGTGTGAGAAGACTTTGTGTGAGTGTGCTGGGGGGCTGGAGTGCGCCTGCCCTGCCCTCCTGGAGTACGCCCGGACCTGTGCCCAGGAGGGAATGGTGCTGTACGGCTGGACCGACCACAGCGCGTGCAGCCCAGTGTGCCCTGCTGGTATGGAGTATAGGCAGTGTGTGTCCCCTTGCGCCAGGACCTGCCAGAGCCTGCACATCAATGAAATGTGTCAGGAGCGATGCGTGGATGGCTGCAGCTGCCCTGAGGGACAGCTCCTGGATGAAGGCCTCTGCGTGGAGAGCACCGAGTGTCCCTGCGTGCATTCCGGAAAGCGCTACCCTCCCGGCACCTCCCTCTCTCGAGACTGCAACACCTGCATTTGCCGAAACAGCCAGTGGATCTGCAGCAATGAAGAATGTCCAGGGGAGTGCCTTGTCACAGGTCAATCACACTTCAAGAGCTTTGACAACAGATACTTCACCTTCAGTGGGATCTGCCAGTACCTGCTGGCCCGGGATTGCCAGGACCACTCCTTCTCCATTGTCATTGAGACTGTCCAGTGTGCTGATGACCGCGACGCTGTGTGCACCCGCTCCGTCACCGTCCGGCTGCCTGGCCTGCACAACAGCCTTGTGAAACTGAAGCATGGGGCAGGAGTTGCCATGGATGGCCAGGACGTCCAGCTCCCCCTCCTGAAAGGTGACCTCCGCATCCAGCATACAGTGACGGCCTCCGTGCGCCTCAGCTACGGGGAGGACCTGCAGATGGACTGGGATGGCCGCGGGAGGCTGCTGGTGAAGCTGTCCCCCGTCTATGCCGGGAAGACCTGCGGCCTGTGTGGGAATTACAATGGCAACCAGGGCGACGACTTCCTTACCCCCTCTGGGCTGGCGGAGCCCCGGGTGGAGGACTTCGGGAACGCCTGGAAGCTGCACGGGGACTGCCAGGACCTGCAGAAGCAGCACAGCGATCCCTGCGCCCTCAACCCGCGCATGACCAGGTTCTCCGAGGAGGCGTGCGCGGTCCTGACGTCCCCCACATTCGAGGCCTGCCATCGTGCCGTCAGCCCGCTGCCCTACCTGCGGAACTGCCGCTACGACGTGTGCTCCTGCTCGGACGGCCGCGAGTGCCTGTGCGGCGCCCTGGCCAGCTATGCCGCGGCCTGCGCGGGGAGAGGCGTGCGCGTCGCGTGGCGCGAGCCAGGCCGCTGTGAGCTGAACTGCCCGAAAGGCCAGGTGTACCTGCAGTGCGGGACCCCCTGCAACCTGACCTGCCGCTCTCTCTCTTACCCGGATGAGGAATGCAATGAGGCCTGCCTGGAGGGCTGCTTCTGCCCCCCAGGGCTCTACATGGATGAGAGGGGGGACTGCGTGCCCAAGGCCCAGTGCCCCTGTTACTATGACGGTGAGATCTTCCAGCCAGAAGACATCTTCTCAGACCATCACACCATGTGCTACTGTGAGGATGGCTTCATGCACTGTACCATGAGTGGAGTCCCCGGAAGCTTGCTGCCTGACGCTGTCCTCAGCAGTCCCCTGTCTCATCGCAGCAAAAGGAGCCTATCCTGTCGGCCCCCCATGGTCAAGCTGGTGTGTCCCGCTGACAACCTGCGGGCTGAAGGGCTCGAGTGTACCAAAACGTGCCAGAACTATGACCTGGAGTGCATGAGCATGGGCTGTGTCTCTGGCTGCCTCTGCCCCCCGGGCATGGTCCGGCATGAGAACAGATGTGTGGCCCTGGAAAGGTGTCCCTGCTTCCATCAGGGCAAGGAGTATGCCCCTGGAGAAACAGTGAAGATTGGCTGCAACACTTGTGTCTGTCGGGACCGGAAGTGGAACTGCACAGACCATGTGTGTGATGCCACGTGCTCCACGATCGGCATGGCCCACTACCTCACCTTCGACGGGCTCAAATACCTGTTCCCCGGGGAGTGCCAGTACGTTCTGGTGCAGGATTACTGCGGCAGTAACCCTGGGACCTTTCGGATCCTAGTGGGGAATAAGGGATGCAGCCACCCCTCAGTGAAATGCAAGAAACGGGTCACCATCCTGGTGGAGGGAGGAGAGATTGAGCTGTTTGACGGGGAGGTGAATGTGAAGAGGCCCATGAAGGATGAGACTCACTTTGAGGTGGTGGAGTCTGGCCGGTACATCATTCTGCTGCTGGGCAAAGCCCTCTCCGTGGTCTGGGACCGCCACCTGAGCATCTCCGTGGTCCTGAAGCAGACATACCAGGAGAAAGTGTGTGGCCTGTGTGGGAATTTTGATGGCATCCAGAACAATGACCTCACCAGCAGCAACCTCCAAGTGGAGGAAGACCCTGTGGACTTTGGGAACTCCTGGAAAGTGAGCTCGCAGTGTGCTGACACCAGAAAAGTGCCTCTGGACTCATCCCCTGCCACCTGCCATAACAACATCATGAAGCAGACGATGGTGGATTCCTCCTGTAGAATCCTTACCAGTGACGTCTTCCAGGACTGCAACAAGCTGGTGGACCCCGAGCCATATCTGGATGTCTGCATTTACGACACCTGCTCCTGTGAGTCCATTGGGGACTGCGCCTGCTTCTGCGACACCATTGCTGCCTATGCCCACGTGTGTGCCCAGCATGGCAAGGTGGTGACCTGGAGGACGGCCACATTGTGCCCCCAGAGCTGCGAGGAGAGGAATCTCCGGGAGAACGGGTATGAGTGTGAGTGGCGCTATAACAGCTGTGCACCTGCCTGTCAAGTCACGTGTCAGCACCCTGAGCCACTGGCCTGCCCTGTGCAGTGTGTGGAGGGCTGCCATGCCCACTGCCCTCCAGGGAAAATCCTGGATGAGCTTTTGCAGACCTGCGTTGACCCTGAAGACTGTCCAGTGTGTGAGGTGGCTGGCCGGCGTTTTGCCTCAGGAAAGAAAGTCACCTTGAATCCCAGTGACCCTGAGCACTGCCAGATTTGCCACTGTGATGTTGTCAACCTCACCTGTGAAGCCTGCCAGGAGCCGGGAGGCCTGGTGGTGCCTCCCACAGATGCCCCGGTGAGCCCCACCACTCTGTATGTGGAGGACATCTCGGAACCGCCGTTGCACGATTTCTACTGCAGCAGGCTACTGGACCTGGTCTTCCTGCTGGATGGCTCCTCCAGGCTGTCCGAGGCTGAGTTTGAAGTGCTGAAGGCCTTTGTGGTGGACATGATGGAGCGGCTGCGCATCTCCCAGAAGTGGGTCCGCGTGGCCGTGGTGGAGTACCACGACGGCTCCCACGCCTACATCGGGCTCAAGGACCGGAAGCGACCGTCAGAGCTGCGGCGCATTGCCAGCCAGGTGAAGTATGCGGGCAGCCAGGTGGCCTCCACCAGCGAGGTCTTGAAATACACACTGTTCCAAATCTTCAGCAAGATCGACCGCCCTGAAGCCTCCCGCATCACCCTGCTCCTGATGGCCAGCCAGGAGCCCCAACGGATGTCCCGGAACTTTGTCCGCTACGTCCAGGGCCTGAAGAAGAAGAAGGTCATTGTGATCCCGGTGGGCATTGGGCCCCATGCCAACCTCAAGCAGATCCGCCTCATCGAGAAGCAGGCCCCTGAGAACAAGGCCTTCGTGCTGAGCAGTGTGGATGAGCTGGAGCAGCAAAGGGACGAGATCGTTAGCTACCTCTGTGACCTTGCCCCTGAAGCCCCTCCTCCTACTCTGCCCCCCGACATGGCACAAGTCACTGTGGGCCCGGGGCTCTTGGGGGTTTCGACCCTGGGGCCCAAGAGGAACTCCATGGTTCTGGATGTGGCGTTCGTCCTGGAAGGATCGGACAAAATTGGTGAAGCCGACTTCAACAGGAGCAAGGAGTTCATGGAGGAGGTGATTCAGCGGATGGATGTGGGCCAGGACAGCATCCACGTCACGGTGCTGCAGTACTCCTACATGGTGACTGTGGAGTACCCCTTCAGCGAGGCACAGTCCAAAGGGGACATCCTGCAGCGGGTGCGAGAGATCCGCTACCAGGGCGGCAACAGGACCAACACTGGGCTGGCCCTGCGGTACCTCTCTGACCACAGCTTCTTGGTCAGCCAGGGTGACCGGGAGCAGGCGCCCAACCTGGTCTACATGGTCACCGGAAATCCTGCCTCTGATGAGATCAAGAGGCTGCCTGGAGACATCCAGGTGGTGCCCATTGGAGTGGGCCCTAATGCCAACGTGCAGGAGCTGGAGAGGATTGGCTGGCCCAATGCCCCTATCCTCATCCAGGACTTTGAGACGCTCCCCCGAGAGGCTCCTGACCTGGTGCTGCAGAGGTGCTGCTCCGGAGAGGGGCTGCAGATCCCCACCCTCTCCCCTGCACCTGACTGCAGCCAGCCCCTGGACGTGATCCTTCTCCTGGATGGCTCCTCCAGTTTCCCAGCTTCTTATTTTGATGAAATGAAGAGTTTCGCCAAGGCTTTCATTTCAAAAGCCAATATAGGGCCTCGTCTCACTCAGGTGTCAGTGCTGCAGTATGGAAGCATCACCACCATTGACGTGCCATGGAACGTGGTCCCGGAGAAAGCCCATTTGCTGAGCCTTGTGGACGTCATGCAGCGGGAGGGAGGCCCCAGCCAAATCGGGGATGCCTTGGGCTTTGCTGTGCGATACTTGACTTCAGAAATGCATGGTGCCAGGCCGGGAGCCTCAAAGGCGGTGGTCATCCTGGTCACGGACGTCTCTGTGGATTCAGTGGATGCAGCAGCTGATGCCGCCAGGTCCAACAGAGTGACAGTGTTCCCTATTGGAATTGGAGATCGCTACGATGCAGCCCAGCTACGGATCTTGGCAGGCCCAGCAGGCGACTCCAACGTGGTGAAGCTCCAGCGAATCGAAGACCTCCCTACCATGGTCACCTTGGGCAATTCCTTCCTCCACAAACTGTGCTCTGGATTTGTTAGGATTTGCATGGATGAGGATGGGAATGAGAAGAGGCCCGGGGACGTCTGGACCTTGCCAGACCAGTGCCACACCGTGACTTGCCAGCCAGATGGCCAGACCTTGCTGAAGAGTCATCGGGTCAACTGTGACCGGGGGCTGAGGCCTTCGTGCCCTAACAGCCAGTCCCCTGTTAAAGTGGAAGAGACCTGTGGCTGCCGCTGGACCTGCCCCTGCGTGTGCACAGGCAGCTCCACTCGGCACATCGTGACCTTTGATGGGCAGAATTTCAAGCTGACTGGCAGCTGTTCTTATGTCCTATTTCAAAACAAGGAGCAGGACCTGGAGGTGATTCTCCATAATGGTGCCTGCAGCCCTGGAGCAAGGCAGGGCTGCATGAAATCCATCGAGGTGAAGCACAGTGCCCTCTCCGTCGAGCTGCACAGTGACATGGAGGTGACGGTGAATGGGAGACTGGTCTCTGTTCCTTACGTGGGTGGGAACATGGAAGTCAACGTTTATGGTGCCATCATGCATGAGGTCAGATTCAATCACCTTGGTCACATCTTCACATTCACTCCACAAAACAATGAGTTCCAACTGCAGCTCAGCCCCAAGACTTTTGCTTCAAAGACGTATGGTCTGTGTGGGATCTGTGATGAGAACGGAGCCAATGACTTCATGCTGAGGGATGGCACAGTCACCACAGACTGGAAAACACTTGTTCAGGAATGGACTGTGCAGCGGCCAGGGCAGACGTGCCAGCCCATCCTGGAGGAGCAGTGTCTTGTCCCCGACAGCTCCCACTGCCAGGTCCTCCTCTTACCACTGTTTGCTGAATGCCACAAGGTCCTGGCTCCAGCCACATTCTATGCCATCTGCCAGCAGGACAGTTGCCACCAGGAGCAAGTGTGTGAGGTGATCGCCTCTTATGCCCACCTCTGTCGGACCAACGGGGTCTGCGTTGACTGGAGGACACCTGATTTCTGTGCTATGTCATGCCCACCATCTCTGGTCTACAACCACTGTGAGCATGGCTGTCCCCGGCACTGTGATGGCAACGTGAGCTCCTGTGGGGACCATCCCTCCGAAGGCTGTTTCTGCCCTCCAGATAAAGTCATGTTGGAAGGCAGCTGTGTCCCTGAAGAGGCCTGCACTCAGTGCATTGGTGAGGATGGAGTCCAGCACCAGTTCCTGGAAGCCTGGGTCCCGGACCACCAGCCCTGTCAGATCTGCACATGCCTCAGCGGGCGGAAGGTCAACTGCACAACGCAGCCCTGCCCCACGGCCAAAGCTCCCACGTGTGGCCTGTGTGAAGTAGCCCGCCTCCGCCAGAATGCAGACCAGTGCTGCCCCGAGTATGAGTGTGTGTGTGACCCAGTGAGCTGTGACCTGCCCCCAGTGCCTCACTGTGAACGTGGCCTCCAGCCCACACTGACCAACCCTGGCGAGTGCAGACCCAACTTCACCTGCGCCTGCAGGAAGGAGGAGTGCAAAAGAGTGTCCCCACCCTCCTGCCCCCCGCACCGTTTGCCCACCCTTCGGAAGACCCAGTGCTGTGATGAGTATGAGTGTGCCTGCAACTGTGTCAACTCCACAGTGAGCTGTCCCCTTGGGTACTTGGCCTCAACTGCCACCAATGACTGTGGCTGTACCACAACCACCTGCCTTCCCGACAAGGTGTGTGTCCACCGAAGCACCATCTACCCTGTGGGCCAGTTCTGGGAGGAGGGCTGCGATGTGTGCACCTGCACCGACATGGAGGATGCCGTGATGGGCCTCCGCGTGGCCCAGTGCTCCCAGAAGCCCTGTGAGGACAGCTGTCGGTCGGGCTTCACTTACGTTCTGCATGAAGGCGAGTGCTGTGGAAGGTGCCTGCCATCTGCCTGTGAGGTGGTGACTGGCTCACCGCGGGGGGACTCCCAGTCTTCCTGGAAGAGTGTCGGCTCCCAGTGGGCCTCCCCGGAGAACCCCTGCCTCATCAATGAGTGTGTCCGAGTGAAGGAGGAGGTCTTTATACAACAAAGGAACGTCTCCTGCCCCCAGCTGGAGGTCCCTGTCTGCCCCTCGGGCTTTCAGCTGAGCTGTAAGACCTCAGCGTGCTGCCCAAGCTGTCGCTGTGAGCGCATGGAGGCCTGCATGCTCAATGGCACTGTCATTGGGCCCGGGAAGACTGTGATGATCGATGTGTGCACGACCTGCCGCTGCATGGTGCAGGTGGGGGTCATCTCTGGATTCAAGCTGGAGTGCAGGAAGACCACCTGCAACCCCTGCCCCCTGGGTTACAAGGAAGAAAATAACACAGGTGAATGTTGTGGGAGATGTTTGCCTACGGCTTGCACCATTCAGCTAAGAGGAGGACAGATCATGACACTGAAGCGTGATGAGACGCTCCAGGATGGCTGTGATACTCACTTCTGCAAGGTCAATGAGAGAGGAGAGTACTTCTGGGAGAAGAGGGTCACAGGCTGCCCACCCTTTGATGAACACAAGTGTCTGGCTGAGGGAGGTAAAATTATGAAAATTCCAGGCACCTGCTGTGACACATGTGAGGAGCCTGAGTGCAACGACATCACTGCCAGGCTGCAGTATGTCAAGGTGGGAAGCTGTAAGTCTGAAGTAGAGGTGGATATCCACTACTGCCAGGGCAAATGTGCCAGCAAAGCCATGTACTCCATTGACATCAACGATGTGCAGGACCAGTGCTCCTGCTGCTCTCCGACACGGACGGAGCCCATGCAGGTGGCCCTGCACTGCACCAATGGCTCTGTTGTGTACCATGAGGTTCTCAATGCCATGGAGTGCAAATGCTCCCCCAGGAAGTGCAGCAAGTGAGGCTGCTGCAGCTGCATGGGTGCCTGCTGCTGCCTGCCTTGGCCTGATGGCCAGGCCAGAGTGCTGCCAGTCCTCTGCATGTTCTGCTCTTGTGCCCTTCTGAGCCCACAATAAAGGCTGAGCTCTTATCTTGCAAAAGGC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Plasma</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Platelet alpha granule lumen</CellLocal>
      <Ontology_ID>GO:0031093</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Weibel-Palade body</CellLocal>
      <Ontology_ID>GO:0033093</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Proteinaceous extracellular matrix</CellLocal>
      <Ontology_ID>GO:0005578</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum</CellLocal>
      <Ontology_ID>GO:0005783</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>VWF</Gene_Name>
    <Gene_Alias>F8VWF</Gene_Alias>
    <Gene_ID>7450</Gene_ID>
    <Genbank_ACCN>NM_000552</Genbank_ACCN>
    <Protein_ACCN>NP_000543</Protein_ACCN>
    <HGNC_ID>12726</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7450</Gene_URL>
    <UCSC_ID>uc001qnn.1</UCSC_ID>
    <EMBL_ID>ENSG00000110799</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P07359</Uniprot_ID>
      <Gene_Name>GP1BA</Gene_Name>
      <EBI_ID>EBI-297082</EBI_ID>
      <PPI_EBI_URL>EBI-981819,EBI-297082</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q76LX8</Uniprot_ID>
      <Gene_Name>ADAMTS13</Gene_Name>
      <EBI_ID>EBI-981764</EBI_ID>
      <PPI_EBI_URL>EBI-981819,EBI-981764</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Al Amyloidosis</Disease_Name>
      <Disease_Detail>Al Amyloidosis</Disease_Detail>
      <Disease_DB>ALM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/al_amyloidosis?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bernard-Soulier Syndrome</Disease_Name>
      <Disease_Detail>Bernard-Soulier Syndrome</Disease_Detail>
      <Disease_DB>BRN019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bernard_soulier_syndrome?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Von Willebrand Disease, Types 2a, 2b, 2m, and 2n</Disease_Name>
      <Disease_Detail>Von Willebrand's Disease</Disease_Detail>
      <Disease_DB>VNW006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/von_willebrand_disease_types_2a_2b_2m_and_2n?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>African Tick-Bite Fever</Disease_Name>
      <Disease_Detail>African Tick-Bite Fever</Disease_Detail>
      <Disease_DB>AFR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/african_tick_bite_fever?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vulvar Intraepithelial Neoplasia</Disease_Name>
      <Disease_Detail>Vulvar Intraepithelial Neoplasia</Disease_Detail>
      <Disease_DB>VLV044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vulvar_intraepithelial_neoplasia?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acquired Von Willebrand Syndrome</Disease_Name>
      <Disease_Detail>Acquired Von Willebrand Syndrome</Disease_Detail>
      <Disease_DB>ACQ017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acquired_von_willebrand_syndrome?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Afibrinogenemia</Disease_Name>
      <Disease_Detail>Afibrinogenemia</Disease_Detail>
      <Disease_DB>AFB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/afibrinogenemia?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2a Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2a_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Angiopathy</Disease_Name>
      <Disease_Detail>Diabetic Angiopathy</Disease_Detail>
      <Disease_DB>DBT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_angiopathy?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Von Willibrand Disease, Type 3</Disease_Name>
      <Disease_Detail>Von Willebrand's Disease</Disease_Detail>
      <Disease_DB>VNW003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/von_willibrand_disease_type_3?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mild Hemophilia a</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>MLD013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mild_hemophilia_a?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Viii Deficiency</Disease_Name>
      <Disease_Detail>Factor Viii Deficiency</Disease_Detail>
      <Disease_DB>FCT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_viii_deficiency?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Eisenmenger Syndrome</Disease_Name>
      <Disease_Detail>Eisenmenger Syndrome</Disease_Detail>
      <Disease_DB>ESN011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/eisenmenger_syndrome?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Qualitative Platelet Defect</Disease_Name>
      <Disease_Detail>Qualitative Platelet Defect</Disease_Detail>
      <Disease_DB>QLT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/qualitative_platelet_defect?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xii Deficiency</Disease_Name>
      <Disease_Detail>Factor Xii Deficiency</Disease_Detail>
      <Disease_DB>FCT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xii_deficiency?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intermittent Claudication</Disease_Name>
      <Disease_Detail>Intermittent Claudication</Disease_Detail>
      <Disease_DB>INT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intermittent_claudication?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Purpura</Disease_Name>
      <Disease_Detail>Purpura</Disease_Detail>
      <Disease_DB>PRP030</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/purpura?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ullrich Congenital Muscular Dystrophy</Disease_Name>
      <Disease_Detail>Ullrich Congenital Muscular Dystrophy</Disease_Detail>
      <Disease_DB>ULL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ullrich_congenital_muscular_dystrophy?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2m Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2m_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Central Retinal Vein Occlusion</Disease_Name>
      <Disease_Detail>Central Retinal Vein Occlusion</Disease_Detail>
      <Disease_DB>CNT016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/central_retinal_vein_occlusion?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Autoimmune Polyglandular Syndrome Type 3</Disease_Name>
      <Disease_Detail>Autoimmune Polyendocrine Syndrome</Disease_Detail>
      <Disease_DB>ATM061</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/autoimmune_polyglandular_syndrome_type_3?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fainting</Disease_Name>
      <Disease_Detail>Fainting</Disease_Detail>
      <Disease_DB>FNT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fainting?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 1 Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_1_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coronary Thrombosis</Disease_Name>
      <Disease_Detail>Coronary Thrombosis</Disease_Detail>
      <Disease_DB>CRN017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_thrombosis?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Myocardial Infarction</Disease_Name>
      <Disease_Detail>Myocardial Infarction</Disease_Detail>
      <Disease_DB>MYC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/myocardial_infarction?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Thrombotic Thrombocytopenic Purpura</Disease_Name>
      <Disease_Detail>Thrombotic Thrombocytopenic Purpura</Disease_Detail>
      <Disease_DB>THR005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thrombotic_thrombocytopenic_purpura?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemarthrosis</Disease_Name>
      <Disease_Detail>Hemarthrosis</Disease_Detail>
      <Disease_DB>HMR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemarthrosis?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2n Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2n_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Angiodysplasia</Disease_Name>
      <Disease_Detail>Angiodysplasia</Disease_Detail>
      <Disease_DB>ANG011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/angiodysplasia?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 3 Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_3_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2b Von Willebrand Disease</Disease_Name>
      <Disease_Detail>Von Willebrand Disease</Disease_Detail>
      <Disease_DB>TYP015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2b_von_willebrand_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemophilia</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>HMP007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemophilia?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malignant Hypertension</Disease_Name>
      <Disease_Detail>Malignant Hypertension</Disease_Detail>
      <Disease_DB>MLG069</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malignant_hypertension?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Severe Hemophilia a</Disease_Name>
      <Disease_Detail>Hemophilia</Disease_Detail>
      <Disease_DB>SVR056</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/severe_hemophilia_a?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Von Willebrand's Disease</Disease_Name>
      <Disease_Detail>Von Willebrand's Disease</Disease_Detail>
      <Disease_DB>VNW001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/von_willebrands_disease?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Temporal Arteritis</Disease_Name>
      <Disease_Detail>Temporal Arteritis</Disease_Detail>
      <Disease_DB>TMP003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/temporal_arteritis?search=VWF#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Factor Xi Deficiency</Disease_Name>
      <Disease_Detail>Factor Xi Deficiency</Disease_Detail>
      <Disease_DB>FCT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/factor_xi_deficiency?search=VWF#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>The ternary von Willebrand Factor A1-glycoprotein Ibalpha-botrocetin complex</PDB_Title>
      <PDB_ID>1U0N</PDB_ID>
      <Resolution>2.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U0N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation</PubMed_Title>
      <Author>Fukuda, K., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2005)12:152-159</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15665869?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A1 DOMAIN OF VON WILLEBRAND FACTOR</PDB_Title>
      <PDB_ID>1AUQ</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AUQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the von Willebrand Factor A1 domain and implications for the binding of platelet glycoprotein Ib.</PubMed_Title>
      <Author>Emsley, J., et al.</Author>
      <Journal>J.Biol.Chem.(1998)273:10396-10401</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9553097?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the N1602A mutant of an engineered VWF A2 domain (N1493C and C1670S)</PDB_Title>
      <PDB_ID>3PPX</PDB_ID>
      <Resolution>1.91</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PPX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of an engineered VWF A2 domain (N1493C and C1670S)</PDB_Title>
      <PDB_ID>3PPV</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PPV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The von Willebrand Factor mutant (I546V) A1 domain</PDB_Title>
      <PDB_ID>1IJB</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IJB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of von Willebrand factor activation by the snake toxin botrocetin.</PubMed_Title>
      <Author>Fukuda, K., et al.</Author>
      <Journal>Structure(2002)10:943-950</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12121649?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the D1596A/N1602A double mutant of an engineered VWF A2 domain (N1493C and C1670S)</PDB_Title>
      <PDB_ID>3PPY</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PPY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure and Paratope Determination of 82D6A3, an Antithrombotic Antibody Directed Against the von Willebrand factor A3-Domain</PDB_Title>
      <PDB_ID>2ADF</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ADF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain</PubMed_Title>
      <Author>Staelens, S., et al.</Author>
      <Journal>J.Biol.Chem.(2006)281:2225-2231</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16314412?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex of Glycoprotein Ib alpha and the von Willebrand Factor A1 Domain</PDB_Title>
      <PDB_ID>1M10</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1M10</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.</PubMed_Title>
      <Author>Huizinga, E.G., et al.</Author>
      <Journal>Science(2002)297:1176-1179</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12183630?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN IN COMPLEX WITH THE FUNCTION BLOCKING NMC-4 FAB</PDB_Title>
      <PDB_ID>1OAK</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OAK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab.</PubMed_Title>
      <Author>Celikel, R., et al.</Author>
      <Journal>Nat.Struct.Biol.(1998)5:189-194</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9501911?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The von Willebrand Factor mutant (I546V) A1 domain-botrocetin Complex</PDB_Title>
      <PDB_ID>1IJK</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IJK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of von Willebrand factor activation by the snake toxin botrocetin.</PubMed_Title>
      <Author>Fukuda, K., et al.</Author>
      <Journal>Structure(2002)10:943-950</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12121649?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>VON WILLEBRAND FACTOR A2 DOMAIN WITH CALCIUM</PDB_Title>
      <PDB_ID>3ZQK</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZQK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Calcium Modulates Force Sensing by the Von Willebrand Factor A2 Domain.</PubMed_Title>
      <Author>Jakobi, A.J., et al.</Author>
      <Journal>Nat.Commun.(2011)2:385</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21750539?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the von Willebrand factor A3 domain in complex with a collagen III derived triple-helical peptide</PDB_Title>
      <PDB_ID>4DMU</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DMU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for collagen I chain registry from the structure of the collagen von Willebrand factor A3 domain complex.</PubMed_Title>
      <Author>Brondijk, T.H., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2012)109:5253-5258</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22440751?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VWF A2 domain</PDB_Title>
      <PDB_ID>3GXB</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GXB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.</PubMed_Title>
      <Author>Zhang, Q., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:9226-9231</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19470641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A3 DOMAIN OF VON WILLEBRAND FACTOR</PDB_Title>
      <PDB_ID>1AO3</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AO3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The von willebrand factor A3 domain does not contain a metal ion-dependent adhesion site motif.</PubMed_Title>
      <Author>Bienkowska, J., et al.</Author>
      <Journal>J.Biol.Chem.(1997)272:25162-25167</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9312128?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN VON WILLEBRAND FACTOR A3 DOMAIN</PDB_Title>
      <PDB_ID>1ATZ</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ATZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding.</PubMed_Title>
      <Author>Huizinga, E.G., et al.</Author>
      <Journal>Structure(1997)5:1147-1156</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9331419?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of von Willebrand Factor A1 domain complexed with snake venom bitiscetin</PDB_Title>
      <PDB_ID>1UEX</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1UEX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin. Insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins.</PubMed_Title>
      <Author>Maita, N., et al.</Author>
      <Journal>J.Biol.Chem.(2003)278:37777-37781</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12851390?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR A3 DOMAIN IN COMPLEX WITH A FAB FRAGMENT OF IGG RU5 THAT INHIBITS COLLAGEN BINDING</PDB_Title>
      <PDB_ID>1FE8</PDB_ID>
      <Resolution>2.03</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FE8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of the collagen-binding site of the von Willebrand factor A3-domain.</PubMed_Title>
      <Author>Romijn, R.A., et al.</Author>
      <Journal>J.Biol.Chem.(2001)276:9985-9991</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11098050?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Complex of the Wild-type Von Willebrand Factor A1 domain and Glycoprotein Ib alpha at 2.6 Angstrom Resolution</PDB_Title>
      <PDB_ID>1SQ0</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SQ0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations</PubMed_Title>
      <Author>Dumas, J.J., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:23327-23334</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15039442?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with DNA Aptamer ARC1172, an Inhibitor of VWF-Platelet Binding</PDB_Title>
      <PDB_ID>3HXQ</PDB_ID>
      <Resolution>2.69</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HXQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1.</PubMed_Title>
      <Author>Huang, R.H., et al.</Author>
      <Journal>Structure(2009)17:1476-1484</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19913482?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE VON WILLEBRAND FACTOR (VWF) A1 DOMAIN I546V MUTANT IN COMPLEX WITH THE FUNCTION BLOCKING FAB NMC4</PDB_Title>
      <PDB_ID>1FNS</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FNS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule.</PubMed_Title>
      <Author>Celikel, R., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:881-884</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11017197?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Von Willebrand Factor (VWF) A1 Domain in Complex with DNA Aptamer ARC1172, an Inhibitor of VWF-Platelet Binding</PDB_Title>
      <PDB_ID>3HXO</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HXO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1.</PubMed_Title>
      <Author>Huang, R.H., et al.</Author>
      <Journal>Structure(2009)17:1476-1484</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19913482?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the D1596A mutant of an engineered VWF A2 domain (N1493C and C1670S)</PDB_Title>
      <PDB_ID>3PPW</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PPW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel calcium-binding site of von Willebrand factor A2 domain regulates its cleavage by ADAMTS13</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04611</Pathway_ID>
      <Pathway_Title>Platelet activation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04512</Pathway_ID>
      <Pathway_Title>ECM-receptor interaction</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signaling molecules and interaction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a/b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.d.ii.b.b.c.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1ao3</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01330001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>